Elevated pentraxin-3 levels are related to blood pressure levels in hypertensive patients: An observational study;Hipertansif hastalarda artmış pentraxin- 3 seviyelerinin kan basıncı seviyeleri ile ilişkisi: Gözlemsel bir çalışma

Anadolu Kardiyoloji Dergisi

Volumn 12, Issue 4, 2012, Pages 298-304

  Parlak Dr , Adem ^d   Aydoǧan, Ümit ^d   Iyisoy, Atila ^a   Dikililer, Mehmet Aytuǧ ^b   Kut, Altuǧ ^c   Çakir, Erdinç ^a   Saǧlam, Kenan ^a  

^a GULHANE SCHOOL OF MEDICINE   (Turkey)

^b irnak Military Hospital   (Turkey)

^c Ba kent Animal Hospital   (Turkey)

^d NONE

Author keywords

Hypertension; Inflammatory mediators; Pentraxin3; Regression analysis

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; CHOLESTEROL; LIPID; PENTRAXIN 3; SERUM AMYLOID P;

ADULT; ARTICLE; BLOOD PRESSURE MEASUREMENT; BODY MASS; CHEMICAL ANALYSIS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; FEMALE; HUMAN; HYPERTENSION; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PROTEIN BLOOD LEVEL; SYSTOLIC BLOOD PRESSURE; BLOOD; BLOOD PRESSURE; CASE CONTROL STUDY; INFLAMMATION; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY;

ADULT; BLOOD PRESSURE; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; HYPERTENSION; INFLAMMATION; MALE; MIDDLE AGED; SERUM AMYLOID P-COMPONENT;

EID: 84863940809     PISSN: 13028723     EISSN: None     Source Type: Journal    
DOI: 10.5152/akd.2012.092     Document Type: Article

References (29)

1. Cachofeiro V, Miana M, de las Heras N, Martín-Fernández B, Ballesteros S, Balfagón G, et al. Inflammation: a link between hypertension and atherosclerosis. Current Hypertension Reviews 2009; 5: 40-8. [CrossRef]
2. Diep QN, El Mabrouk M, Cohn JS, Endemann D, Amiri F, Virdis A, et al. Structure, endothelial function, cell growth, and inflammation in blood vessels of angiotensin II-infused rats: role of peroxisome proliferator-activated receptor-gamma. Circulation 2002; 105: 2296-302. [CrossRef]
3. Mantovani A, Garlanda C, Doni A, Bottazzi B. Pentraxins in innate immunity: from C-reactive protein to the long pentraxin PTX3. J Clin Immunol 2008; 28: 1-13. [CrossRef]
4. Alles VV, Bottazzi B, Peri G, Golay J, Introna M, Mantovani A. Inducible expression of PTX3, a new member of the pentraxin family, in human mononuclear phagocytes. Blood 1994; 84: 3483-93.
5. Lee GW, Goodman AR, Lee TH, Vilcek J. Relationship of TSG-14 protein to the pentraxin family of major acute phase proteins. J Immunol 1994; 153: 3700-7.
6. Presta M, Camozzi M, Salvatori G, Rusnati M. Role of the soluble pattern recognition receptor PTX3 in vascular biology. J Cell Mol Med 2007; 11: 723-38. [CrossRef]
7. Norata GD, Garlanda C, Catapano AL. The long pentraxin PTX3: a modulator of the immunoinflammatory response in atherosclerosis and cardiovascular diseases. Trends Cardiovasc Med 2010; 20: 35-40. [CrossRef]
8. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42: 1206-52. [CrossRef]
9. Fazzini F, Peri G, Doni A, Dell'Antonio G, Dal Cin E, Bozzolo E, et al. PTX3 in small-vessel vasculitides: an independent indicator of disease activity produced at sides of inflammation. Arthritis Rheum 2001; 44: 2841-50. [CrossRef]
10. Tong M, Carrero JJ, Qureshi AR, Anderstam B, Heimbürger O, Bárány P, et al. Plasma pentraxin 3 in patients with chronic kidney disease: associations with renal function, protein-energy wasting, cardiovascular disease, and mortality. Clin J Am Soc Nephrol 2007; 2: 889-97. [CrossRef]
11. Garlanda C, Bottazzi B, Bastone A, Mantovani A. Pentraxins at the crossroads between innate immunity, inflammation, matrix deposition, and female fertility. Annu Rev Immunol 2005; 23: 337-66. [CrossRef]
12. Peri G, Introna M, Corradi D, Iacuitti G, Signorini S, Avanzini F, et al. PTX3, A prototypical long pentraxin, is an early indicator of acute myocardial infarction in humans. Circulation 2000; 102: 636-41.
13. de Kruiff MD, Limper M, Sierhuis K, Wagenaar JF, Spek CA, Garlanda C, et al. PTX3 predicts severe disease in febrile patients at the emergence department. J Infect 2010; 60: 122-7. [CrossRef]
14. Bevelacqua V, Libra M, Mazzarino MC, Gangemi P, Nicotra G, Curatolo S, et al. Long pentraxin 3: a marker of inflammation in untreated psoriatic patients. Int J Mol Med 2006; 18: 415-23.
15. Inoue K, Sugiyama A, Reid PC, Ito Y, Miyauchi K, Mukai S, et al. Establishment of a high sensitivity plasma assay for human pentraxin 3 as a marker for unstable angina pectoris. Arterioscler Thromb Vasc Biol 2007; 27: 161-7. [CrossRef]
16. Muller B, Peri G, Doni A, Torri V, Landmann R, Bottazzi B, et al. Circulating levels of the long pentraxin PTX 3 correlate with severity of infection in critically ill patients. Crit Care Med 2001; 29: 1404-7. [CrossRef]
17. Üstündaǧ M, Orak M, Güloǧlu C, Sayhan MB, Alyan Ö, Kale E. Comparative diagnostic accuracy of serum levels of neutrophil activating peptide-2 and pentraxin-3 versus troponin-I in acute coronary syndrome. Anadolu Kardiyol Derg 2011; 11: 588-94.
18. Yilmaz MI, Carrero JJ, Martín-Ventura JL, Sönmez A, Saǧlam M, Çelik T, et al. Combined therapy with renin-angiotensin system and calcium channel blockers in type 2 diabetic hypertensive patients with proteinuria: effects on soluble TWEAK, PTX3 and flow-mediated dilatation. Clin J Am Soc Nephrol 2010; 5: 1174-81. [CrossRef]
19. Yilmaz MI, Axelsson J, Sönmez A, Carrero JJ, Saǧlam M, Eyileten T, et al. Effect of renin angiotensin system blockade on pentraxin 3 levels in type-2 diabetic patients with proteinuria. Clin J Am Soc of Nephrol 2009; 4: 535-41. [CrossRef]
20. Alles VV, Bottazzi B, Peri G, Golay J, Introna M, Mantovani A. Inducible expression of PTX3, a new member of the pentraxin family, in human mononuclear phagocytes. Blood 1994; 84: 3483-93.
21. Vouret-Craviari V, Matteucci C, Peri G, Poli G, Introna M, Mantovani A. Expression of a long pentraxin, PTX3, by monocytes exposed to the mycobacterial cell wall component lipoarabinomannan. Infect Immun 1997; 65: 1345-50.
22. Verma S, Wang CH, Li SH, Dumont AS, Fedak PW, Badiwala MV, et al. A self-fulfilling prophercy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation 2002; 106: 913-9. [CrossRef]
23. Jenny NS, Arnold AM, Kuller LH, Tracy RP, Psaty BM. Associations of pentraxin 3 with cardiovascular disease and all-cause death: the Cardiovascular Health Study. Arterioscler Thromb Vasc Biol 2009; 29: 594-9. [CrossRef]
24. Mendall MA, Patel P, Ballam L, Strachan D, Northfield TC. C reactive protein and its relation to cardiovascular risk factors: a population based cross sectional study. BMJ 1996; 312: 1061-5. [CrossRef]
25. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO 3rd, Criqui M, et al. Centers for Disease Control and Prevention; American Heart Association. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003; 107: 499-511. [CrossRef]
26. Bautista LE, López-Jaramillo P, Vera LM, Casas JP, Otero AP, Guaracao AI. Is C-reactive protein an independent risk factor for essential hypertension? J Hypertens 2001; 19: 857-61. [CrossRef]
27. Hingorani AD, Cross J, Kharbanda RK, Mullen MJ, Bhagat K, Taylor M, et al. Acute systemic inflammation impairs endotheliumdependent dilatation in humans. Circulation 2000; 102: 994-9.
28. Fong BS, Rodrigues PO, Salter AM, Yip BP, Despres JP, Angel A, et al. Characterization of high density lipoprotein binding to human adipocyte plasma membranes. J Clin Invest 1985; 75: 1804-12. [CrossRef]
29. Jabs WJ, Lögering BA, Gerke P, Kreft B, Wolber EM, Klinger MH, et al. The kidney as a second site of human C-reactive protein formation in vivo. Eur J Immunol 2003; 33: 152-61. [CrossRef]